Cole C A, Forbes P D, Davies R E
J Am Acad Dermatol. 1984 Oct;11(4 Pt 1):599-606. doi: 10.1016/s0190-9622(84)70213-1.
In 1976 we reported a change in spectral distribution of "blacklight" fluorescent lamps. It was not possible to determine the spectral composition of these lamps by any codes or packaging materials. Phototherapy booths utilizing standard BL-HO lamps will accept lamps of at least two spectral distributions; both types are commercially available. This study was conducted to determine the biologic efficacy of these two lamp types that we refer to as BL-O and BL-N. The BL-O spectrum had a peak emission at approximately 350 nm with 98% of the energy between 320 and 400 nm. The BL-N spectrum had its peak emission at 365 nm with a range from 340 to 400 nm. The BL-O spectrum was at least 2.5 to 4 times as effective as BL-N in causing minimally perceptible phototoxicity in albino hairless mice given oral doses of 8 mg/kg of 8-methoxypsoralen. Food and Drug Administration (FDA)-approved specifications imply that the BL-O spectrum is to be used for psoralens and ultraviolet A (PUVA) phototherapy. If lamps with the BL-N spectrum are replaced by lamps with the BL-O spectrum, the metered dose must be reduced to no more than one-fourth of the previous dose or the patient may suffer serious phototoxic reactions.
1976年，我们报告了“黑光灯”荧光灯光谱分布的变化。通过任何编码或包装材料都无法确定这些灯的光谱组成。使用标准BL-HO灯的光疗箱将接受至少两种光谱分布的灯；这两种类型在市场上均有销售。本研究旨在确定我们称为BL-O和BL-N的这两种灯的生物学功效。BL-O光谱在约350nm处有一个峰值发射，98%的能量在320至400nm之间。BL-N光谱在365nm处有峰值发射，范围为340至400nm。在给白化无毛小鼠口服8mg/kg的8-甲氧基补骨脂素时，BL-O光谱在引起最小可察觉的光毒性方面至少比BL-N有效2.5至4倍。美国食品药品监督管理局（FDA）批准的规范表明，BL-O光谱应用于补骨脂素和紫外线A（PUVA）光疗。如果将具有BL-N光谱的灯替换为具有BL-O光谱的灯，计量剂量必须减少到不超过先前剂量的四分之一，否则患者可能会遭受严重的光毒性反应。
